Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Purpose: The purpose of the study is to examine if treatment with liothyronine increases left ventricular ejection fraction (LVEF) in patients with stable, chronic heart failure.
The patients are examined 3 times. At baseline, after 3 months and after 6 months.After the examination is performed, they begin the study medication while admitted at Dept. of Cardiology, Herlev Hospital, for cardiac monitoring.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo-liothyronine | Placebo Comparator | 3 months of placebo followed by 3 months of Liothyronine treatment. |
|
| Liothyronine-Placebo | Other | 3 months of Liothyronine treatment followed by 3 months of Placebo treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Liothyronine | Drug | Liothyronine 40 microgram per day |
|
| Measure | Description | Time Frame |
|---|---|---|
| left ventricle ejection fraction | The effect of liothyronine treatment in low dose in 3 months on LVEF. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Body composition | The effect of 3 months low dose liothyronine treatment on body composition in patients with heart failure. | 3 months |
| Quality of Life, questionaire | The effect of 3 months low dose liothyronine treatment on quality of life, assessed by SF-36 and Minnesota Living with Heart Failure questionnaires in patients with heart failure. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jens Faber, MDSci | Herlev Hospital, Dept. of Endocrinology | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Herlev Hospital, Dept. of Endocrinology | Herlev | 2730 | Denmark |
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| D005067 | Euthyroid Sick Syndromes |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D013959 | Thyroid Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014284 | Triiodothyronine |
| ID | Term |
|---|---|
| D013970 | Thyronines |
| D013963 | Thyroid Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Liothyronine | Drug | 3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral) |
|
|
| 3 months |
| YKL-40, YNF-alpha, hsCRP and IL-6 | The effect of 3 months low dose liothyronine treatment on low grade inflammation assessed by measurement of pro-inflammatory markers in patients with heart failure. | 3 months |
| RBP 4, HBA1C, adiponectin (high and low weight), glucose and HOMA-1 | The effect of 3 months low dose liothyronine treatment on metabolic status in patients with heart failure. | 3 months |
| GDF 8, SHBG, CK and PINP | The effect of 3 months low dose liothyronine treatment on the extrathyroidal thyroid effect in patients with heart failure. | 3 months |
| NT-proBNP, EDV and ESV | The effect of 3 months low dose liothyronine treatment on heart function in patients with heart failure. | 3 months |
| D013974 | Thyroxine |
| D024322 | Amino Acids, Aromatic |
| D000598 | Amino Acids, Cyclic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |